Percheron Therapeutics Limited (ASX:PER)

Market Cap	7.93M +4.2%
Revenue (ttm)	843.60K -53.2%
Net Income	-4.79M
EPS	-0.00
Shares Out	1.98B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	414,157
Open	0.0035
Previous Close	0.0030
Day's Range	0.0035 - 0.0040
52-Week Range	0.0020 - 0.0100
Beta	1.00
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PER

Financial Performance

In fiscal year 2026, Percheron Therapeutics's revenue was 843,600, a decrease of -53.16% compared to the previous year's 1.80 million. Losses were -4.79 million, -67.89% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error